JP7697933B2 - ５－（４－（（２ｓ，５ｓ）－５－（４－クロロベンジル）－２－メチルモルホリノ）ピペリジン－１－イル）－１ｈ－１，２，４－トリアゾール－３－アミンの製造プロセス - Google Patents

５－（４－（（２ｓ，５ｓ）－５－（４－クロロベンジル）－２－メチルモルホリノ）ピペリジン－１－イル）－１ｈ－１，２，４－トリアゾール－３－アミンの製造プロセス Download PDF

Info

Publication number
JP7697933B2
JP7697933B2 JP2022519042A JP2022519042A JP7697933B2 JP 7697933 B2 JP7697933 B2 JP 7697933B2 JP 2022519042 A JP2022519042 A JP 2022519042A JP 2022519042 A JP2022519042 A JP 2022519042A JP 7697933 B2 JP7697933 B2 JP 7697933B2
Authority
JP
Japan
Prior art keywords
formula
compound
chlorobenzyl
piperidin
methylmorpholino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022519042A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022549863A (ja
JP2022549863A5 (https=
Inventor
ヴィトコフスキ グルゼゴルツ
マグディッチ マルタ
ティシュキエヴィッチ マグダレーナ
ザクシェフスキ マーティン
ピカル スタニスラウ
Original Assignee
オンコアレンディ セラピューティクス エス．エー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オンコアレンディ セラピューティクス エス．エー． filed Critical オンコアレンディ セラピューティクス エス．エー．
Publication of JP2022549863A publication Critical patent/JP2022549863A/ja
Publication of JP2022549863A5 publication Critical patent/JP2022549863A5/ja
Application granted granted Critical
Publication of JP7697933B2 publication Critical patent/JP7697933B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2022519042A 2019-09-25 2020-09-25 ５－（４－（（２ｓ，５ｓ）－５－（４－クロロベンジル）－２－メチルモルホリノ）ピペリジン－１－イル）－１ｈ－１，２，４－トリアゾール－３－アミンの製造プロセス Active JP7697933B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962905494P 2019-09-25 2019-09-25
PL43126919 2019-09-25
PLP.431269 2019-09-25
US62/905,494 2019-09-25
PCT/IB2020/058984 WO2021059220A1 (en) 2019-09-25 2020-09-25 Process for the production of 5-(4-((2 s,5 s)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1 h-1,2,4-triazol-3-amine

Publications (3)

Publication Number Publication Date
JP2022549863A JP2022549863A (ja) 2022-11-29
JP2022549863A5 JP2022549863A5 (https=) 2023-06-08
JP7697933B2 true JP7697933B2 (ja) 2025-06-24

Family

ID=73139065

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022519042A Active JP7697933B2 (ja) 2019-09-25 2020-09-25 ５－（４－（（２ｓ，５ｓ）－５－（４－クロロベンジル）－２－メチルモルホリノ）ピペリジン－１－イル）－１ｈ－１，２，４－トリアゾール－３－アミンの製造プロセス

Country Status (16)

Country Link
US (2) US11746107B2 (https=)
EP (1) EP4041726B8 (https=)
JP (1) JP7697933B2 (https=)
KR (1) KR20220069008A (https=)
CN (1) CN114466845B (https=)
AU (1) AU2020356534B2 (https=)
BR (1) BR112022005420A2 (https=)
CA (1) CA3155177A1 (https=)
ES (1) ES3056105T3 (https=)
IL (1) IL291569B2 (https=)
MX (1) MX2022002881A (https=)
PH (1) PH12022550713A1 (https=)
PL (1) PL4041726T3 (https=)
TW (3) TWI769532B (https=)
WO (1) WO2021059220A1 (https=)
ZA (1) ZA202204542B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022002881A (es) 2019-09-25 2022-06-08 Oncoarendi Therapeutics Sa Proceso para la produccion de 5-(4-((2s,5s)-5-(4-clorobencil)-2-me tilmorfolino)piperidin-1-il)-1h-1,2,4-triazol-3-amina.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018526399A (ja) 2015-09-04 2018-09-13 オンコアレンディ セラピューティクス エス．エー． ヒトキチナーゼ阻害剤として有用な置換アミノトリアゾール

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2802530B1 (fr) * 1999-12-17 2002-02-22 Sanofi Synthelabo Nouveaux derives amino substitues ramifies du 3-amino-1-phenyl-1h[1,2,4]triazole, procedes pour leur preparation et compositions pharmaceutiques les contenant
ATE354568T1 (de) * 2000-08-08 2007-03-15 Ortho Mcneil Pharm Inc Nicht-imidazol aryloxypiperidine als h3 rezeptor liganden
PE20142366A1 (es) * 2012-05-30 2015-01-10 Hoffmann La Roche Compuestos triazolo como inhibidores de pde 10
EP3082805B1 (en) * 2013-12-20 2020-02-05 Institute for Drug Discovery, LLC Substituted amino triazoles, and methods using same
US9440953B2 (en) 2014-12-19 2016-09-13 OncoArendi Therapeutics Sp. z o.o. Substituted amino triazoles useful as acidic mammalian chitinase inhibitors
GB201513740D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonist
MX2022000306A (es) 2019-07-15 2022-03-11 Oncoarendi Therapeutics Sa Amino triazoles sustituidos utiles como inhibidores de quitinasa.
MX2022002881A (es) 2019-09-25 2022-06-08 Oncoarendi Therapeutics Sa Proceso para la produccion de 5-(4-((2s,5s)-5-(4-clorobencil)-2-me tilmorfolino)piperidin-1-il)-1h-1,2,4-triazol-3-amina.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018526399A (ja) 2015-09-04 2018-09-13 オンコアレンディ セラピューティクス エス．エー． ヒトキチナーゼ阻害剤として有用な置換アミノトリアゾール

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J. Med. Chem.，2019年07月，Vol.62，pp.7126-7145
J. Org. Chem.，1985年，Vol.50，pp.1927-1932
第４版 実験化学講座２６ 有機合成ＶＩＩＩ －不斉合成・還元・糖・標識化合物－，1992年，pp.206-215

Also Published As

Publication number Publication date
JP2022549863A (ja) 2022-11-29
PL4041726T3 (pl) 2026-02-23
ZA202204542B (en) 2023-01-25
EP4041726B1 (en) 2025-09-17
EP4041726A1 (en) 2022-08-17
CN114466845B (zh) 2024-12-17
IL291569B1 (en) 2024-12-01
EP4041726C0 (en) 2025-09-17
TW202448877A (zh) 2024-12-16
IL291569A (en) 2022-05-01
PH12022550713A1 (en) 2024-02-12
IL291569B2 (en) 2025-04-01
WO2021059220A1 (en) 2021-04-01
CA3155177A1 (en) 2021-04-01
EP4041726B8 (en) 2025-11-26
US20210147401A1 (en) 2021-05-20
CN114466845A (zh) 2022-05-10
TW202126644A (zh) 2021-07-16
TWI769532B (zh) 2022-07-01
US20240025889A1 (en) 2024-01-25
BR112022005420A2 (pt) 2022-06-21
AU2020356534A1 (en) 2022-05-19
TWI849432B (zh) 2024-07-21
ES3056105T3 (en) 2026-02-18
US11746107B2 (en) 2023-09-05
US12319677B2 (en) 2025-06-03
MX2022002881A (es) 2022-06-08
AU2020356534B2 (en) 2026-04-09
KR20220069008A (ko) 2022-05-26
TWI892762B (zh) 2025-08-01
TW202237594A (zh) 2022-10-01

Similar Documents

Publication Publication Date Title
CN102985416B (zh) 制备凝血酶特异性抑制剂的方法
JP6832946B2 (ja) キナーゼ阻害剤およびその中間体の調製方法
JP2022183220A (ja) Ａｇ－１０、その中間体及びその塩の調製方法
WO2014093583A2 (en) Synthetic methods for preparing 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, other salt forms of this compound and intermediates thereof
JP6873053B2 (ja) タンパク質脱アセチル化阻害剤の製造方法
US20170137384A1 (en) Process for the preparation of kinase inhibitors and intermediates thereof
JP7697933B2 (ja) ５－（４－（（２ｓ，５ｓ）－５－（４－クロロベンジル）－２－メチルモルホリノ）ピペリジン－１－イル）－１ｈ－１，２，４－トリアゾール－３－アミンの製造プロセス
CN101657437B (zh) 制备左西替利嗪及其中间体的新方法
EP3413891A1 (en) Processes for the preparation of highly pure prucalopride succinate and its intermediates
WO2020053795A2 (en) Process for the preparation of acalabrutinib and its intermediates
JP2001521498A (ja) Ｏ−（３−アミノ−２−ヒドロキシ−プロピル）−ヒドロキシミック酸ハロゲン化物の製造方法
JP2022549863A5 (https=)
HK40080939A (en) Process for the production of 5-(4-((2 s,5 s)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1 h-1,2,4-triazol-3-amine
HK40080939B (en) Process for the production of 5-(4-((2 s,5 s)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1 h-1,2,4-triazol-3-amine
KR101123281B1 (ko) 치환된 벤즈아미드 유도체 및 그의 약제학상 허용되는 염의제조방법
US11858901B2 (en) 3-((R)-2-(amino-2-phenylethyl)-1-(2-fluoro-6 trifluoromethyl benzyl)-5-iodo-6-methyl-1H-pyrimidine-2,4-dione or a salt thereof, process for its preparation, and its use in the synthesis of elagolix
CA3214107A1 (en) New process for the synthesis of 5-{5-chloro-2-[(3s)-3- [(morpholin-4-yl)methyl]-3,4-dihydroisoquinoline-2(1h)- carbonyl]phenyl}-1,2-dimethyl-1h-pyrrole-3-carboxylic acid derivatives and its application for the production of pharmaceutical compounds
KR20160060188A (ko) 솔리페나신 또는 그 염의 결정형 제조방법, 이에 사용되는 신규 중간체 및 그 제조방법
US20060252940A1 (en) Crystalline 1-[2-(2,4-difluorophenyl)-oxiranyl methyl]-1h-1,2,4-triazole
WO2019098551A1 (ko) 의약품 합성용 중간체 화합물의 제조 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230531

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230531

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240528

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250523

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250603

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250612

R150 Certificate of patent or registration of utility model

Ref document number: 7697933

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150